Tengen Biomedical Co
Biotech · Private
Vertebrate-specific replication-defective dengue virus (VSRD-DENV) as a single-cycle vaccine candidate against all four dengue serotypes
- Grants
- $4.9M
- 9 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2017201820192020202120222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Development of Zika viral pseudoinfectious virus as Zika vaccine candidate | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of Zika viral pseudoinfectious virus as Zika vaccine candidate | $652,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of Zika viral pseudoinfectious virus as Zika vaccine candidate | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of Zika viral pseudoinfectious virus as Zika vaccine candidate | $52,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a ZIKA viral pseudoinfectious virus as ZIKA vaccine candidate (STTR Phase II) | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing Vertebrate-Specific Replication-Defective Dengue Virus as Novel Single-CycleDengue Vaccine Candidate | $298,530 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a ZIKA viral pseudoinfectious virus as ZIKA vaccine candidate (STTR Phase II) | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing Vertebrate-Specific Replication-Defective Dengue Virus as Novel Single-CycleDengue Vaccine Candidate | $298,530 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a ZIKA viral pseudoinfectious virus as ZIKA vaccine candidate (STTR Phase II) | $1,000,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1192 | PreveCeutical Medical Inc. | — | $254K |
| 1193 | KELIOMICS, INC. | — | $250K |
| 1194 | ELF ZONE, INC. | — | — |
| 1195 | Tengen Biomedical Co | — | — |
| 1196 | VICOLINE MEDICAL, LLC | — | — |
| 1197 | Khartis Therapeutics | — | — |
| 1198 | TATEVA THERAPEUTICS INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.